Criteria Established for Western Blot Diagnosis of Lyme Disease
By LabMedica International staff writers Posted on 20 Sep 2011 |
The laboratory diagnosis of Lyme borreliosis (LB) has been dependent mainly on serology with the Western blot test used for confirmation.
To ensure the best use of the Western blot in a routine diagnostic laboratory it is essential that the entire interpretation process remains as simple as possible as a consensus for the interpretation of Western blots to detect Borrelia burgdorferi infection in Europe has been difficult to obtain.
Scientists at the UK National Lyme Borreliosis Testing Service Laboratory, at Raigmore Hospital (Inverness, Scotland) endeavored to interpret what bands are classed as specific, the number of bands needed for a positive result, the role of band intensity combined with clinical information. In 2008, 3,688 patients (4,223 serum samples) were tested by enzyme immunoassay (EIA), with 832 patients tested by confirmatory in-house immunoglobulin IgG Western blot. For a Western blot-positive result, these criteria required at least four bands in total, including the 41 kDa band and a further two specific bands with strong intensity. They found that 272 patients were Western blot-positive, 170 were weak positive, 156 were equivocal, and 234 were negative.
All sera were screened by commercial B. burgdorferi IgM/IgG EIA utilizing B. burgdorferi (B31 strain) antigen produced by Zeus Scientific, (Branchburg, NJ, USA) and the accurate identification of band molecular weight was routinely determined using polyclonal sera obtained from Abcam (Cambridge, UK) and well-categorized Western blot-positive sera. A new interpretation criteria and a testing algorithm were then developed. The revised criteria changed the results in 109/3,688 (3%) patients and produced significantly more Western blot-positive and weak-positive patients than with the current criteria. In total, 76 patients who were negative or equivocal became positive, which may have led to a change in their management. Conversely, 33 patients who were weak-positive became equivocal, but their management may not have been affected.
The most important specific Western blot bands appear to be 20 kDa, 28 kDa, 41 kDa, and 48 kDa, but other maybe as significant. The authors concluded that the revised criteria have simplified blot interpretation and improved the sensitivity and robustness of their Western blot method. Using a protocol tailored to patients that incorporates clinical characteristics means that the entire process will be easier and will aid the management of patients. The study was accepted for publication on August 27, 2011, in the British Journal of Biomedical Science.
Related Links:
UK National Lyme Borreliosis Testing Service
Zeus Scientific
Abcam
To ensure the best use of the Western blot in a routine diagnostic laboratory it is essential that the entire interpretation process remains as simple as possible as a consensus for the interpretation of Western blots to detect Borrelia burgdorferi infection in Europe has been difficult to obtain.
Scientists at the UK National Lyme Borreliosis Testing Service Laboratory, at Raigmore Hospital (Inverness, Scotland) endeavored to interpret what bands are classed as specific, the number of bands needed for a positive result, the role of band intensity combined with clinical information. In 2008, 3,688 patients (4,223 serum samples) were tested by enzyme immunoassay (EIA), with 832 patients tested by confirmatory in-house immunoglobulin IgG Western blot. For a Western blot-positive result, these criteria required at least four bands in total, including the 41 kDa band and a further two specific bands with strong intensity. They found that 272 patients were Western blot-positive, 170 were weak positive, 156 were equivocal, and 234 were negative.
All sera were screened by commercial B. burgdorferi IgM/IgG EIA utilizing B. burgdorferi (B31 strain) antigen produced by Zeus Scientific, (Branchburg, NJ, USA) and the accurate identification of band molecular weight was routinely determined using polyclonal sera obtained from Abcam (Cambridge, UK) and well-categorized Western blot-positive sera. A new interpretation criteria and a testing algorithm were then developed. The revised criteria changed the results in 109/3,688 (3%) patients and produced significantly more Western blot-positive and weak-positive patients than with the current criteria. In total, 76 patients who were negative or equivocal became positive, which may have led to a change in their management. Conversely, 33 patients who were weak-positive became equivocal, but their management may not have been affected.
The most important specific Western blot bands appear to be 20 kDa, 28 kDa, 41 kDa, and 48 kDa, but other maybe as significant. The authors concluded that the revised criteria have simplified blot interpretation and improved the sensitivity and robustness of their Western blot method. Using a protocol tailored to patients that incorporates clinical characteristics means that the entire process will be easier and will aid the management of patients. The study was accepted for publication on August 27, 2011, in the British Journal of Biomedical Science.
Related Links:
UK National Lyme Borreliosis Testing Service
Zeus Scientific
Abcam
Latest Microbiology News
- New Test Diagnoses Bacterial Meningitis Quickly and Accurately
- Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
Channels
Clinical Chemistry
view channel
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
A tumor marker is a substance found in the body that may signal the presence of cancer. These substances, which can include proteins, genes, molecules, or other biological compounds, are either produced... Read more
Urine Test Diagnoses Early-Stage Prostate Cancer
Prostate cancer is one of the leading causes of death among men worldwide. A major challenge in diagnosing the disease is the absence of reliable biomarkers that can detect early-stage tumors.... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read moreTechnology
view channel
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more